



Issued: Sept 10, 2009



PRESS RELEASE

ORAQIX LAUNCHED IN AUSTRALIA

Oraqix, the subgingival anaesthetic gel from DENTSPLY, has finally been launched in Australia, providing a needle-free anaesthetic alternative for managing patient anxiety and pain during non surgical periodontal debridement.

Oraqix is already extensively used in the United States and Europe where its efficacy has been demonstrated via a range of clinical trials.

The gel consists of an eutectic mixture of Lignocaine and Prilocaine in a new thermosetting system. It is delivered as a liquid directly into the periodontal pocket via the purpose-designed Oraqix dispenser, using a blunt-tipped applicator. When it makes contact with the periodontal pocket it instantly sets into a gel, providing up to 30 minutes of anaesthesia after a fast 30 second onset.

In Australia, Oraqix has been indicated for use in adults during probing, scaling and/or root planing and according to DENTSPLY it is a less-invasive option for the many Australians who suffer from anxiety and stress associated with dental treatment and injections.

“Research from the Australian Research Centre for Population Oral Health reveals that 2.5 million Australians suffer from high dental fear¹ and many more worry about pain and needles,” explained Dr Pamela Dalglish, DENTSPLY Professional Services Manager.

“Data also shows that around 2/3 of patients associate pain and unpleasantness with the scaling of gingival pockets² and we know that patients don’t like needles, whether it is the actual needle, numbness of surrounding tissues or the post-op trauma such as lip and cheek biting, swelling and parasthesia.

¹ “Vicious cycle of dental fear, exploring the interplay between oral health, service utilisation and dental fear”. Armfield, Stewart and Spencer. BMC Oral Health 2007

² “Efficacy of a topical anaesthetic on pain and unpleasantness during scaling of gingival pockets”, Svensson et al, Anesth Prog 41:35- 39 1994



“Oraqix will provide greater comfort and less stress for these patients, which will in turn give dentists, periodontists and hygienists greater control during the procedure, potentially reducing chairside time and improving the likelihood of recall visits.”

Oraqix can be applied to the full mouth in one visit or in isolated sites for both initial therapy and maintenance procedures. It is supplied in a carton of 20 single application cartridges with 20 blunt-tipped applicators for use with the Oraqix dispenser. It is easy to load and easy to administer and can be reapplied if required.

For further information and orders, contact: DENTSPLY Australia on 1300 55 29 29 or email: clientservices@dentsply.com



The Consumer Medicines Information can be found on www.Dentsply.com.au. Oraqix is not listed on the PBS. Dental clinicians should review the Product Information for full prescribing information before use.



For further information, or to arrange an interview with a DENTSPLY spokesperson, please contact:

Kelly Ward
Ward Communications Pty Ltd
T. 03 9744 1855
M. 0407 860- 834
E. kward@wardcom.com.au

